09May 2021
Cardiovascular effects of SGLT‐2 inhibitors and GLP‐1 receptor agonists: the P–value and beyond

Cardiovascular effects of SGLT‐2 inhibitors and GLP‐1 receptor agonists: the P–value and beyond

Despite growing awareness of the dangers of a dichotomous interpretation of trial results based on the “statistical significance” of a treatment effect, the uptake of new approaches has been slow in diabetes medicine. We showcase a number of ways to interpret the evidence for a treatment effect applied to the cardiovascular outcome trials of glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) and sodium‐glucose co‐transporter‐2 inhibitors (SGLT‐2is)...

  • #endo-diabetology

Like

Save

Share